These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30469350)

  • 1. Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies.
    Johnson DE
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.
    Desoubeaux G; Reichert JM; Sleeman M; Reckamp KL; Ryffel B; Adamczewski JP; Sweeney TD; Vanbever R; Diot P; Owen CA; Page C; Lerondel S; Le Pape A; Heuze-Vourc'h N
    MAbs; 2016; 8(6):999-1009. PubMed ID: 27266390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
    Lynch CM; Hart BW; Grewal IS
    MAbs; 2009; 1(1):2-11. PubMed ID: 20046568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.
    Lansita JA; Mounho-Zamora B
    Curr Pain Headache Rep; 2015; 19(2):2. PubMed ID: 25681157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
    van Meer PJ; Kooijman M; Brinks V; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H
    MAbs; 2013; 5(5):810-6. PubMed ID: 23924803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.
    Everds NE; Tarrant JM
    Toxicol Pathol; 2013 Feb; 41(2):280-302. PubMed ID: 23471185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.
    Kloks C; Berger C; Cortez P; Dean Y; Heinrich J; Bjerring Jensen L; Koppenburg V; Kostense S; Kramer D; Spindeldreher S; Kirby H
    J Immunol Methods; 2015 Feb; 417():1-9. PubMed ID: 25602137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies.
    Brennan FR; Kiessling A
    Toxicol In Vitro; 2017 Dec; 45(Pt 3):296-308. PubMed ID: 28263892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics.
    Xue L; Rup B
    AAPS J; 2013 Jul; 15(3):893-6. PubMed ID: 23761225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.
    Brennan FR; Morton LD; Spindeldreher S; Kiessling A; Allenspach R; Hey A; Muller PY; Frings W; Sims J
    MAbs; 2010; 2(3):233-55. PubMed ID: 20421713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?
    Hassanein M; Partridge MA; Shao W; Torri A
    Bioanalysis; 2020 Sep; 12(18):1325-1336. PubMed ID: 32946271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
    Karle A; Spindeldreher S; Kolbinger F
    MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of immune complex-mediated hypersensitivity reactions with biotherapeutics in the non-human primate: Critical parameters, safety and lessons for future studies.
    Kronenberg S; Husar E; Schubert C; Freichel C; Emrich T; Lechmann M; Giusti AM; Regenass F
    Regul Toxicol Pharmacol; 2017 Aug; 88():125-137. PubMed ID: 28624430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SEC Based Method for Size Determination of Immune Complexes of Therapeutic Antibodies in Animal Matrix.
    Boysen M; Schlicksupp L; Dreher I; Loebbert R; Richter M
    J Immunol Res; 2016; 2016():9096059. PubMed ID: 27556050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.
    Kizhedath A; Wilkinson S; Glassey J
    Arch Toxicol; 2017 Apr; 91(4):1595-1612. PubMed ID: 27766364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacology and therapeutic applications of monoclonal antibodies.
    Castelli MS; McGonigle P; Hornby PJ
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00535. PubMed ID: 31859459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.
    Sewell F; Chapman K; Couch J; Dempster M; Heidel S; Loberg L; Maier C; Maclachlan TK; Todd M; van der Laan JW
    MAbs; 2017 Jul; 9(5):742-755. PubMed ID: 28475417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.
    Flego M; Ascione A; Cianfriglia M; Vella S
    BMC Med; 2013 Jan; 11():4. PubMed ID: 23289632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.